AUPH (Aurinia Pharmaceuticals Inc)
Insider Trading Activity
Every open-market purchase and sale reported by AUPH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-25 | Stephen P. Robertson | Chief Legal Officer | Sell | — | — |
| 2026-06-08 | Jeffrey Allen Bailey | Director | A | — | — |
| 2026-06-08 | Tina Susan Nova | Director | A | — | — |
| 2026-06-08 | Craig A Johnson | Director | A | — | — |
| 2026-06-08 | Kathleen Goetz | Director | A | — | — |
| 2026-06-02 | TANG CAPITAL MANAGEMENT LLC | 10%+ Owner | Buy | — | — |
| 2026-05-20 | Stephen P. Robertson | Chief Legal Officer | A | — | — |
| 2026-05-20 | Michael S Hearne | Chief Financial Officer | A | — | — |
| 2026-05-20 | Ryan Cole | Chief Operating Officer | A | — | — |
| 2026-03-10 | Greg Keenan | SVP, Chief Medical Officer | F | — | — |
| 2026-03-03 | Peter Greenleaf | Chief Executive Officer | MIXED | — | — |
| 2026-03-03 | Stephen P. Robertson | EVP, General Counsel | MIXED | — | — |
| 2026-03-03 | Joseph M Miller | Chief Financial Officer | MIXED | — | — |
| 2026-03-03 | Matthew Maxwell Donley | Chief Operating Officer | MIXED | — | — |
| 2026-03-03 | Greg Keenan | SVP, Chief Medical Officer | A | — | — |
| 2026-03-03 | KEVIN TANG | Director | Buy | — | — |
| 2026-02-23 | Stephen P. Robertson | EVP, General Counsel | F | — | — |
| 2026-02-23 | Matthew Maxwell Donley | Chief Operating Officer | F | — | — |
| 2026-02-23 | Peter Greenleaf | Chief Executive Officer | F | — | — |
| 2026-02-23 | Joseph M Miller | Chief Financial Officer | F | — | — |
| 2026-02-03 | Greg Keenan | SVP, Chief Medical Officer | F | — | — |
| 2026-01-05 | Stephen P. Robertson | EVP, General Counsel | MIXED | — | — |
| 2026-01-05 | Matthew Maxwell Donley | Chief Operating Officer | MIXED | — | — |
| 2026-01-05 | Joseph M Miller | Chief Financial Officer | MIXED | — | — |
| 2026-01-05 | Peter Greenleaf | Chief Executive Officer | MIXED | — | — |
| 2025-11-24 | Jeffrey Allen Bailey | Director | F | — | — |
| 2025-11-24 | Craig A Johnson | Director | F | — | — |
| 2025-08-05 | Greg Keenan | Chief Medical Officer | Sell | — | — |
| 2025-08-05 | KEVIN TANG | Director | Buy | — | — |
| 2025-05-16 | Craig A Johnson | Director | A | — | — |
| 2025-05-16 | Kathleen Goetz | Director | A | — | — |
| 2025-05-16 | Jeffrey Allen Bailey | Director | A | — | — |
| 2025-05-16 | Tina Susan Nova | Director | A | — | — |
| 2025-03-07 | Greg Keenan | Chief Medical Officer | Sell | — | — |
| 2025-03-04 | Matthew Maxwell Donley | Chief Operating Officer | MIXED | — | — |
| 2025-03-04 | Joseph M Miller | Chief Financial Officer | MIXED | — | — |
| 2025-03-04 | Stephen P. Robertson | EVP, General Counsel | MIXED | — | — |
| 2025-03-04 | Greg Keenan | Chief Medical Officer | MIXED | — | — |
| 2025-03-04 | Peter Greenleaf | Chief Executive Officer | MIXED | — | — |
| 2025-03-04 | KEVIN TANG | Director | Buy | — | — |
| 2024-12-09 | KEVIN TANG | Director | Buy | — | — |
| 2024-11-25 | David R.W. Jayne | Director | A | — | — |
| 2024-11-25 | Jill Leversage | Director | A | — | — |
| 2024-11-25 | Karen L. Smith | Director | A | — | — |
| 2024-11-25 | Jeffrey Allen Bailey | Director | A | — | — |
| 2024-11-25 | Craig A Johnson | Director | A | — | — |
| 2024-11-12 | Jeffrey Allen Bailey | Director | MIXED | — | — |
| 2024-11-12 | Karen L. Smith | Director | MIXED | — | — |
| 2024-08-08 | Scott Michael Habig | Chief Commercial Officer | Sell | — | — |
| 2024-05-22 | Daniel Billen | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 12,838,002 | — |
| — | Director | 12,229,500 | — |
| — | Chief Executive Officer | 1,941,269 | — |
| — | Chief Operating Officer | 680,299 | — |
| — | Chief Financial Officer | 613,932 | — |
| — | Chief Legal Officer | 600,787 | — |
| — | Chief Commercial Officer | 456,338 | — |
| — | EVP, Research and Development | 319,128 | — |
| — | Chief Business Officer | 259,162 | — |
| — | SVP, Chief Medical Officer | 154,449 | — |
| — | Chief Operating Officer | 116,144 | — |
| — | Chief Financial Officer | 116,144 | — |
| — | Chief Medical Officer | 90,953 | — |
| — | Director | 78,733 | — |
| — | EVP of Research | 69,379 | — |
| — | Director | 56,499 | — |
| — | Director | 50,000 | — |
| — | Director | 28,141 | — |
| — | Director | 26,053 | — |
| — | Director | 24,807 | — |
| — | Director | 22,775 | — |
| — | Director | 18,595 | — |
| — | Director | 17,523 | — |
| — | Director | 14,592 | — |
| — | Chief Commercial Officer | 13,495 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AUPH quote page; the site-wide leaderboard is on the insider transactions hub.